(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.75%.
Vaxcyte's earnings in 2026 is -$1,064,261,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$1,262,315,173, with the lowest PCVX earnings forecast at -$1,430,584,182, and the highest PCVX earnings forecast at -$967,159,904. On average, 12 Wall Street analysts forecast PCVX's earnings for 2027 to be -$996,028,128, with the lowest PCVX earnings forecast at -$1,672,660,608, and the highest PCVX earnings forecast at -$171,870,096.
In 2028, PCVX is forecast to generate -$963,811,786 in earnings, with the lowest earnings forecast at -$1,671,202,316 and the highest earnings forecast at -$670,293,375.